Coupling of 5-fluoro 2'-deoxyuridine to lactosaminated poly-l-lysine: an approach to a regional, non-invasive chemotherapy of liver micrometastases.
Nucleoside analogs conjugated with galactosyl-terminating peptides selectively enter liver cells and after intracellular release from the carrier partly exit into bloodstream, resulting in higher concentrations in liver blood than in systemic circulation. The aim of the present experiments was to ascertain whether, in mice injected with non-toxic doses of a 5-fluoro 2'-deoxyuridine (FUdR) conjugate with lactosaminated poly-L-lysine (L-poly(LYS)), the drug was released by hepatic cells in high enough amounts to be pharmacologically active on neoplastic cells infiltrating the liver. We observed that L-poly(LYS)-FUdR inhibited the growth of hepatic metastases induced by intrasplenic administration of murine colon carcinoma C-26 cells. L-poly(LYS)-FUdR was not toxic for C-26 cells in vitro, was selectively taken up by mouse liver, and was stable in mouse blood, indicating that the effect on the metastases was due to FUdR (and/or its active metabolites) released in liver blood after the conjugate was taken up by the hepatic cells. These results suggest that L-poly(LYS)-FUdR might be useful in adjuvant chemotherapy of tumors giving liver metastases. The drug released from hepatic cells into liver blood following conjugate administration via the peripheral venous route might accomplish a locoregional, non-invasive treatment of micrometastases nourished by liver sinusoids.
Di Stefano
G
G
Department of Experimental Pathology, University of Bologna, Via San Giacomo 14, 40126, Bologna, Italy.
Busi
C
C
Camerino
A
A
Derenzini
M
M
Trerè
D
D
Fiume
L
L
D000606:Amino Sugars / Q000737:chemistry; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004355:Drug Stability; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011107:Polylysine / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D000606:Amino Sugars; D000964:Antimetabolites, Antineoplastic; D004337:Drug Carriers; D005467:Floxuridine; C032233:lactosamine; D011107:Polylysine